Inkstone Feibo Acquisition Withdraws $60M IPO

Inkstone Feibo Acquisition in a letter to the SEC said it is withdrawing an offering of 6 million units initiall registered in May 2022.

The SPAC said in its original S-1 filing that it would focus on opportunities in biotechnology and green technology industries with an emphasize on Environmental, Social and Governance (“ESG”) practices in the United States and Taiwan. Inkstone Feibo said it would not do a deal with any company based in or having a majority of operations in China, Hong Kong or Macau.

CEO and Chairman I-Fa Chang in 2012 founded Inkstone Capital Co., Ltd., a technology-focused investment advisory firm serving clients in Mainland China, Hong Kong and Taiwan. Read more.

Total
0
Shares
Related Posts
Read More

Achari Ventures I Files Prospectus on $176M Vaso Deal

The target is a diversified medical technology company with several specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture and sale of proprietary medical devices.